Keywords: raptiva, impresses, psoriasis, study, usa-based, biotechnology, major

Raptiva impresses in psoriasis study

Article | 12 February 2007

Print This

USA-based biotechnology major Genentech says that a Phase IV study of its psoriasis treatment Raptiva (efalizumab) showed that the drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in